The key catalysts for the stock going forward would be approval for gAbraxane, respiratory, peptide assets in the US markets, revival of growth in domestic branded formulation space, brokerage said.
Colourful capsules arranged for photograph. (Source: pxhere.com)
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.